Safety assessment of cyclin-dependent kinase 4/6 inhibitors and comparison of time to adverse events
Our research corroborates the typical adverse events linked to CDK4/6 inhibitors while highlighting potential safety concerns in their real-world clinical application.
Authors
- Yingzi Xia (ORCID: https://orcid.org/0009-0005-0885-6959)
- Dingwen Cao
- Shuangshung Zhang (ORCID: https://orcid.org/0009-0005-5065-8278)
- Renmin Zhang (ORCID: https://orcid.org/0000-0002-1019-6735)
Institutions
- Xiamen University (CN)
- Lishui City People's Hospital (CN)
Publication Details
- Journal
- PLoS ONE
- Published
- 2025-11-19
- DOI
- https://doi.org/10.1371/journal.pone.0336767
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00